Episode 266: 265. Semaglutide and Cardiovascular Events in Non-Diabetics (secondary prevention) SELECT TRIAL

The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis.

Improvement in

nonfatal stroke was not statistically significant

death from cardiovascular causes was no significant but

hold on it does appear nonfatal MI was significant and is what really drove the entire composite outcome

All the way down to the discussion to find “An important limitation of this trial is that we included only patients with preexisting cardiovascular disease. The effects of semaglutide on primary prevention of cardiovascular events in persons with overweight or obesity but without previous atherosclerotic disease were not studied. “

And that is because if you want to know the inclusion criteria you have to go to the supplementary data—

WHICH NO ONE DOES

This was sneaky and planned and terrible on the part of Novo Nordisk.

https://www.nejm.org/doi/10.1056/NEJMoa2307563?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed